00:01 , May 23, 2019 |  BioCentury  |  Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners, which the San Diego company plans to use to bring...
19:17 , May 15, 2019 |  BC Innovations  |  Translation in Brief

Optimizing base editors to reduce RNA edits

Two Beam co-founders, Keith Joung and David Liu, have separately optimized CRISPR-guided base editors to reduce off-target RNA editing, which, along with unwanted DNA edits, is an emerging problem for the gene engineering tools. Beam...
23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Beam raises $135M series B

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
12:11 , Mar 6, 2019 |  BioCentury  |  Finance

Beam broadens base with $135M B round

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
04:22 , Nov 8, 2018 |  BC Extra  |  Preclinical News

Machine learning tool predicts template-free CRISPR editing

CRISPR veteran David Liu of the Broad Institute of MIT and Harvard and colleagues have developed a machine learning algorithm that predicts the genotypic result of CRISPR-mediated DNA breaks, suggesting CRISPR-based editing could be achieved...
17:43 , Oct 26, 2018 |  BC Week In Review  |  Company News

NIH doles out over $80M in grants for genome editing

NIH awarded 21 grants on Oct. 9 from its Somatic Cell Genome Editing program, which launched in January. The grants, comprising $86 million over the next five years, are the first to be awarded through...